journal
MENU ▼
Read by QxMD icon Read
search

Hormones & Cancer

journal
https://www.readbyqxmd.com/read/29071575/time-until-partial-response-in-metastatic-adrenocortical-carcinoma-long-term-survivors
#1
Delphine Vezzosi, Christine Do Cao, Ségolène Hescot, Jérôme Bertherat, Magali Haissaguerre, Vanina Bongard, Delphine Drui, Christelle De La Fouchardière, Frédéric Illouz, Françoise Borson-Chazot, Bodale Djobo, Amandine Berdelou, Antoine Tabarin, Martin Schlumberger, Claire Briet, Philippe Caron, Sophie Leboulleux, Rossella Libe, Eric Baudin
A partial response (PR) has been proposed as a surrogate for overall survival in advanced adrenocortical carcinoma (ACC). The primary endpoint of the study was to characterize the time until a PR in patients with metastatic ACC treated with a standard therapy is achieved. Long-term survivors were selected to allow evaluation of delayed tumor response to mitotane. Records from patients with metastatic ACC that survived for > 24 months were retrieved. Tumor response was analyzed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1...
October 25, 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/29052171/statin-use-and-breast-cancer-prognosis-in-black-and-white-women
#2
Amanda Leiter, Nina A Bickell, Derek LeRoith, Anupma Nayak, Sheldon M Feldman, Neil B Friedman, Alison Estabrook, Tari A King, Kezhen Fei, Rebeca Franco, Emily J Gallagher
Studies show decreased risk of breast cancer recurrence and improved survival with statin use, but data on racial disparities regarding breast cancer prognosis and statin use are lacking. Our objective was to investigate if racial disparities in breast cancer prognosis can be partially explained by differences in pre-diagnosis statin use. Patients were identified from a prospective, multicenter study examining the effects of metabolic factors on breast cancer prognosis in Black and White women. Statin use, prognosis (as measured by Nottingham Prognostic Index), anthropometric, tumor, and socio-demographic characteristics were examined...
October 19, 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28980157/expression-of-the-cholecystokinin-b-receptor-in-neoplastic-gastric-cells
#3
Patricia Mjønes, Ivar S Nordrum, Øystein Sørdal, Liv Sagatun, Reidar Fossmark, Arne Sandvik, Helge L Waldum
Gastric cancer is an important disease due to its high mortality. Despite the decline in frequency, most cases are discovered late in its course, and most of the cancer patients die within a few years of diagnosis. In addition to Helicobacter pylori gastritis, gastrin is considered an important factor in the development of this disease, and thus, cholecystokinin-B receptor (CCKBR) becomes of interest. The aim of our study was to explore whether CCKBR is expressed in stomach cancers. Thirty-seven tumors from 19 men and 18 women diagnosed with either adenocarcinoma or neuroendocrine neoplasm (NENs) were included in this study...
October 4, 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28929346/o-glcnac-dependent-regulation-of-progesterone-receptor-function-in-breast-cancer
#4
Gloria M Trinca, Merit L Goodman, Evangelia K Papachristou, Clive S D'Santos, Prabhakar Chalise, Rashna Madan, Chad Slawson, Christy R Hagan
Emerging clinical trial data implicate progestins in the development of breast cancer. While the role for the progesterone receptor (PR) in this process remains controversial, it is clear that PR, a steroid-activated nuclear receptor, alters the transcriptional landscape of breast cancer. PR interacts with many different types of proteins, including transcriptional co-activators and co-repressors, transcription factors, nuclear receptors, and proteins that post-translationally modify PR (i.e., kinases and phosphatases)...
September 19, 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28971320/expression-of-genes-for-methylxanthine-pathway-associated-enzymes-accompanied-by-sex-steroid-receptor-status-impacts-breast-carcinoma-progression
#5
James L Wittliff, Seth B Sereff, Michael W Daniels
Consumption of methylxanthine alkaloids appears to induce activities by antagonizing adenosine receptors, implicated in breast cancer behavior in vitro. Our goal was to evaluate expression of genes for methylxanthine receptors and metabolizing enzymes to assess risk of breast carcinoma recurrence. Clinical outcomes, estrogen/progestin receptor results, and gene expression assays guided selection. RNA was isolated from laser capture microdissection-procured carcinoma cells for microarray using established protocols...
December 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28924876/inhibitory-effects-of-antagonists-of-growth-hormone-releasing-hormone-ghrh-in-thyroid-cancer
#6
Helena Pópulo, Bruno Nunes, Cristina Sampaio, Rui Batista, Marta Teixeira Pinto, Tiago B Gaspar, Leandro Miranda-Alves, Ren-Zhi Cai, Xian Yang Zhang, Andrew V Schally, Manuel Sobrinho-Simões, Paula Soares
Growth hormone-releasing hormone (GHRH) is a peptide hormone secreted by the hypothalamus that regulates the synthesis and secretion of growth hormone (GH) in the pituitary. The extra-hypothalamic GHRH and its cognate receptors (GHRHR and splice variants) play a mitogenic role by stimulating cell proliferation and preventing apoptotic cell death. It is well established that GHRH antagonists inhibit the growth, tumorigenicity, and metastasis of various human malignancies. In this work, we studied the effect of two new GHRH antagonists, MIA602 and MIA690, on thyroid cancer...
December 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28916994/parity-and-risk-of-thyroid-cancer-a-population-based-study-in-lithuania
#7
L Zabuliene, D Jasilionis, E Miseikyte-Kaubriene, R Stukas, A Kaceniene, G Smailyte
An association between parity and thyroid cancer risk has been investigated in a number of independent studies but yielded contradictory findings. The aim of this study was to explore the association between parity and thyroid cancer risk. The population-based cohort study in Lithuanian was conducted. The study dataset based on the linkages between all records from the 2001 population census, all cancer incidence records from the Lithuanian Cancer Registry, and all death and emigration records from Statistics Lithuania for the period between 6 April 2001 and 31 December 2009...
December 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28786001/maternal-resveratrol-treatment-reduces-the-risk-of-mammary-carcinogenesis-in-female-offspring-prenatally-exposure-to-2-3-7-8-tetrachlorodibenzo-p-dioxin
#8
Tássia C de Lima E Silva, Livia T R da Silveira, Mariana F Fragoso, Flávia R M da Silva, Meire F Martinez, Joyce R Zapaterini, Odair H G Diniz, Wellerson R Scarano, Luis F Barbisan
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) presents adverse effects on breast development/carcinogenesis. This study aimed to identify the ability of resveratrol (Res) to modify the adverse effects of TCDD in a female offspring. Pregnant female Wistar rats were allocated into four groups: TCDD, TCDD + Res, Res, and control. TCDD (1 μg/kg) was orally administered as a single dose on gestational day (GD) 15, and Res was orally administered during GD10-21 and lactation at a dose of 20 mg/kg/day. Female offsprings were euthanized on a specific postnatal day (PND) for hormonal analysis (PND 22, 48-51), vaginal opening (PND 30-48), and mammary gland morphology (PND 22)...
December 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28748315/interferon-alpha-treatment-for-disease-control-in-metastatic-pheochromocytoma-paraganglioma-patients
#9
Julien Hadoux, Marie Terroir, Sophie Leboulleux, Frederic Deschamps, Abir Al Ghuzlan, Ségolène Hescot, Lambros Tselikas, Isabelle Borget, Caroline Caramella, Desirée Déandréis, Diane Goere, Thierry De Baere, Martin Schlumberger, Eric Baudin
Interferon-alpha (IFN-alpha) is recommended in neuroendocrine tumors (NET). Malignant pheochromocytoma and paragangliomas (MPPGLs) constitute a rare subgroup of NET with few treatment options. IFN-alpha efficacy in patients with MPPGLs was evaluated in a single-center retrospective study. Progression-free survival (PFS) was the primary endpoint according to RECIST 1.1 and/or PERCIST 1.0, and response rate, safety, and symptomatic efficacy were secondary endpoints. Fourteen patients received peginterferon alfa-2a (90 to 180 μg/week) or interferon alfa-2b (1...
December 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28741260/the-androgen-receptor-supports-tumor-progression-after-the-loss-of-ovarian-function-in-a-preclinical-model-of-obesity-and-breast-cancer
#10
Elizabeth A Wellberg, L Allyson Checkley, Erin D Giles, Stevi J Johnson, Robera Oljira, Reema Wahdan-Alaswad, Rebecca M Foright, Greg Dooley, Susan M Edgerton, Sonali Jindal, Ginger C Johnson, Jennifer K Richer, Peter Kabos, Ann D Thor, Pepper Schedin, Paul S MacLean, Steven M Anderson
The androgen receptor (AR) has context-dependent roles in breast cancer growth and progression. Overall, high tumor AR levels predict a favorable patient outcome, but several studies have established a tumor promotional role for AR, particularly in supporting the growth of estrogen receptor positive (ER-positive) breast cancers after endocrine therapy. Our previous studies have demonstrated that obesity promotes mammary tumor progression after ovariectomy (OVX) in a rat model of postmenopausal breast cancer...
December 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28639228/role-of-20-hydroxyeicosatetraenoic-acid-20-hete-in-androgen-mediated-cell-viability-in-prostate-cancer-cells
#11
Cecilia Colombero, Daniela Papademetrio, Paula Sacca, Eduardo Mormandi, Elida Alvarez, Susana Nowicki
20-Hydroxyeicosatetraenoic acid (20-HETE) is generated intracellularly through the ω-hydroxylation of arachidonic acid by the cytochrome P450 (in humans, CYP4A11 and CYP4F2). 20-HETE induces mitogenic responses in different cancer cells. The aim of this study was to analyze how 20-HETE impacts cell survival, proliferation, and apoptosis in prostate cancer cells. Incubation of the human androgen-sensitive cells (LNCaP) with 1-10 μM HET0016 (a selective inhibitor of 20-HETE synthesis) reduced cell viability by 49*-64%* (*p < 0...
August 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28634910/the-complex-biology-of-the-aryl-hydrocarbon-receptor-and-its-role-in-the-pituitary-gland
#12
REVIEW
Robert Formosa, Josanne Vassallo
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor best known for its ability to mediate the effects of environmental toxins such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD or dioxin), polycyclic aromatic hydrocarbons (PAHs), benzene, and polychlorinated biphenyls (PCBs) through the initiation of transcription of a number of metabolically active enzymes. Therefore, the AHR has been studied mostly in the context of xenobiotic signaling. However, several studies have shown that the AHR is constitutively active and plays an important role in general cell physiology, independently of its activity as a xenobiotic receptor and in the absence of exogenous ligands...
August 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28577282/estrogen-receptor-%C3%AE-modulation-of-the-er%C3%AE-p53-loop-regulating-gene-expression-proliferation-and-apoptosis-in-breast-cancer
#13
Wenwen Lu, Benita S Katzenellenbogen
Estrogen receptor α (ERα) is a crucial transcriptional regulator in breast cancer, but estrogens mediate their effects through two estrogen receptors, ERα and ERβ, subtypes that have contrasting regulatory actions on gene expression and the survival and growth of breast cancer cells. Here, we examine the impact of ERβ on the ERα-p53 loop in breast cancer. We found that ERβ attenuates ERα-induced cell proliferation, increases apoptosis, and reverses transcriptional activation and repression by ERα. Further, ERβ physically interacts with p53, reduces ERα-p53 binding, and antagonizes ERα-p53-mediated transcriptional regulation...
August 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28577281/acquired-tamoxifen-resistance-in-mcf-7-breast-cancer-cells-requires-hyperactivation-of-eif4f-mediated-translation
#14
Dedra H Fagan, Lynsey M Fettig, Svetlana Avdulov, Heather Beckwith, Mark S Peterson, Yen-Yi Ho, Fan Wang, Vitaly A Polunovsky, Douglas Yee
While selective estrogen receptor modulators, such as tamoxifen, have contributed to increased survival in patients with hormone receptor-positive breast cancer, the development of resistance to these therapies has led to the need to investigate other targetable pathways involved in oncogenic signaling. Approval of the mTOR inhibitor everolimus in the therapy of secondary endocrine resistance demonstrates the validity of this approach. Importantly, mTOR activation regulates eukaryotic messenger RNA translation...
August 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28567703/alcohol-intake-and-risk-of-breast-cancer-by-histologic-subtype-and-estrogen-receptor-status-among-women-aged-55-to-74%C3%A2-years
#15
Michelle L Baglia, Kathleen E Malone, Mei-Tzu C Tang, Christopher I Li
Previous studies suggest that alcohol consumption and risk of breast cancer may differ by histologic subtype and hormone receptor status, though results are not entirely consistent. In this population-based case-control study, we evaluated the association between alcohol consumption and risk of invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and invasive ductal-lobular carcinoma (IDLC) overall and by estrogen receptor (ER) status, among women aged 55-74 years of age. Using polytomous regression, associations between current alcohol consumption, overall and by type of alcohol, and breast cancer risk were evaluated in 891 controls and 905 IDC, 567 ILC, and 489 IDLC cases...
August 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28516379/panobinostat-enhances-growth-suppressive-effects-of-progestin-on-endometrial-carcinoma-by-increasing-progesterone-receptor-and-mitogen-inducible-gene-6
#16
Hirofumi Ando, Tsutomu Miyamoto, Hiroyasu Kashima, Shotaro Higuchi, Koichi Ida, David Hamisi Mvunta, Tanri Shiozawa
Although progestin has been used to treat endometrial hyperplasia and endometrial carcinoma (EC), its therapeutic efficacy is limited. In order to improve this, the underlining mechanisms of the effects of progestin need to be elucidated in more detail. In the present study, we examined the involvement of mitogen-inducible gene-6 (MIG6), a negative regulator of the EGF receptor, in the progestin-mediated growth suppression of endometrial epithelia. The immunohistochemical expression of MIG6 was elevated in the early to mid-secretory phases of normal endometrium and also with endometrial hyperplasia after medroxyprogesterone acetate (MPA) therapy...
August 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28396979/nanoparticulate-tetrac-inhibits-growth-and-vascularity-of-glioblastoma-xenografts
#17
Thangirala Sudha, Dhruba J Bharali, Stewart Sell, Noureldien H E Darwish, Paul J Davis, Shaker A Mousa
Thyroid hormone as L-thyroxine (T4) stimulates proliferation of glioma cells in vitro and medical induction of hypothyroidism slows clinical growth of glioblastoma multiforme (GBM). The proliferative action of T4 on glioma cells is initiated nongenomically at a cell surface receptor for thyroid hormone on the extracellular domain of integrin αvβ3. Tetraiodothyroacetic acid (tetrac) is a thyroid hormone derivative that blocks T4 action at αvβ3 and has anticancer and anti-angiogenic activity. Tetrac has been covalently bonded via a linker to a nanoparticle (Nanotetrac, Nano-diamino-tetrac, NDAT) that increases the potency of tetrac and broadens the anticancer properties of the drug...
June 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28396978/a-novel-strategy-to-co-target-estrogen-receptor-and-nuclear-factor-%C3%AE%C2%BAb-pathways-with-hybrid-drugs-for-breast-cancer-therapy
#18
Irida Kastrati, Marton I Siklos, Svitlana D Brovkovych, Gregory R J Thatcher, Jonna Frasor
Nearly 75% of breast tumors express estrogen receptor (ER), and will be treated with endocrine therapy, such as selective estrogen receptor modulator (SERM), tamoxifen, or aromatase inhibitors. Despite their proven success, as many as 40-50% of ER+ tumors fail to respond to endocrine therapy and eventually recur as aggressive, metastatic cancers. Therefore, preventing and/or overcoming endocrine resistance in ER+ tumors remains a major clinical challenge. Deregulation or activation of the nuclear factor κB (NFκB) pathway has been implicated in endocrine resistance and poor patient outcome in ER+ tumors...
June 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28349385/risk-of-gonadoblastoma-development-in-patients-with-turner-syndrome-with-cryptic-y-chromosome-material
#19
Ahreum Kwon, Sei Eun Hyun, Mo Kyung Jung, Hyun Wook Chae, Woo Jung Lee, Tae Hyuk Kim, Duk Hee Kim, Ho-Seong Kim
Current guidelines recommend that testing for Y chromosome material should be performed only in patients with Turner syndrome harboring a marker chromosome and exhibiting virilization in order to detect individuals who are at high risk of gonadoblastoma. However, cryptic Y chromosome material is suggested to be a risk factor for gonadoblastoma in patients with Turner syndrome. Here, we aimed to estimate the frequency of cryptic Y chromosome material in patients with Turner syndrome and determine whether Y chromosome material increased the risk for development of gonadoblastoma...
June 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28293855/growth-hormone-receptor-knockdown-sensitizes-human-melanoma-cells-to-chemotherapy-by-attenuating-expression-of-abc-drug-efflux-pumps
#20
Reetobrata Basu, Nicholas Baumgaertel, Shiyong Wu, John J Kopchick
Melanoma remains one of the most therapy-resistant forms of human cancer despite recent introductions of highly efficacious targeted therapies. The intrinsic therapy resistance of human melanoma is largely due to abundant expression of a repertoire of xenobiotic efflux pumps of the ATP-binding cassette (ABC) transporter family. Here, we report that GH action is a key mediator of chemotherapeutic resistance in human melanoma cells. We investigated multiple ABC efflux pumps (ABCB1, ABCB5, ABCB8, ABCC1, ABCC2, ABCG1, and ABCG2) reportedly associated with melanoma drug resistance in different human melanoma cells and tested the efficacy of five different anti-cancer compounds (cisplatin, doxorubicin, oridonin, paclitaxel, vemurafenib) with decreased GH action...
June 2017: Hormones & Cancer
journal
journal
42676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"